Definitive Contract 75F40120C00028
Award Date 4/1/20
Potential Completion Date 4/5/21
Potential Value $288K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Irvine, CA 92612, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Food and Drug Administration awarded a $996,000 firm fixed-price delivery order to Illumina, Inc. for a MiSeq Sequencer and associated reagents on September 15, 2014, with an ultimate completion date of September 13, 2017. The award was issued to the San Diego-based biotechnology company without set-aside designation, reflecting Illumina's specialized position as the primary provider of next-generation DNA and RNA sequencing technologies to federal agencies. The delivery order procures...
- The Department of Health and Human Services Food and Drug Administration awarded a $19,283.10 firm fixed price purchase order to Illumina, Inc. to provide Illumina ISEQ 100 Systems. The ISEQ 100 Systems will be used for quality control and rebalancing of samples in sample pools. The systems are compatible with Illumina's library preparation kits and provide fast, cost-effective small-scale runs. The place of performance is Illumina's facilities in San Diego, California, and the period of...
- The Food and Drug Administration awarded a purchase order to Illumina, Inc. for one whole genome sequencing instrument on June 25, 2026, at a fixed price of $53,442.90. The procurement was conducted on a sole-source basis under FAR Part 12 as a commercial product acquisition. The order specifies an Illumina MiSeq i100 sequencing system with training for up to three personnel and a one-year manufacturer's warranty covering parts, labor, and operational support. The system must support...
- The Food and Drug Administration awarded a delivery order valued at $81,810 to Illumina, Inc. for a MiSeq instrument on March 16, 2015, with completion scheduled for September 13, 2017. This firm fixed-price delivery order, placed without set-aside designation, procures one of Illumina's established DNA sequencing platforms commonly used in genomic research and diagnostic applications. The MiSeq system is a mid-throughput sequencing instrument suitable for targeted sequencing projects, microbial...
- This firm fixed-price purchase order in the amount of $115,987.29 was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the provision of a MiniSeq System, reagents, and post-warranty services, with a performance period ending on September 30, 2016. While the original solicitation is not provided, the products and services being delivered under this contract can be...
- This federal contract award by the Department of Health and Human Services Food and Drug Administration adds $110,510.96 in funding to an original requisition with Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents. The contract is a firm fixed price Delivery Order with no set-aside designation. Illumina has previously provided sequencing systems, consumables, and support services to various government agencies for research and diagnostics. This award likely supports...
- The Department of Health and Human Services Food and Drug Administration awarded a $457,531.00 firm fixed price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract is for the delivery of an ILLUMINA NEXTSEQ 2000 SEQUENCING SYSTEM, plus a preventative maintenance agreement, to be performed in Silver Spring, Maryland. This award does not have a set-aside designation. Illumina has a history of providing sequencing systems and related...
- The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents, to provide an Illumina MiniSeq DNA/RNA Next Generation Sequencer (NGS) device plus four years of post-warranty maintenance support. The total potential value of the contract is $86,106.00. This procurement was not set-aside for any particular business size or type. The contract...
- The Food and Drug Administration awarded a firm fixed price purchase order valued at $534,536 to Illumina, Inc., a San Diego-based biotechnology company specializing in genomic sequencing technologies, for one Illumina NextSeq 2000 Sequencer with post-warranty correction and remedial repair services. The contract, awarded on August 17, 2023, with an ultimate completion date of December 11, 2028, was issued under a combined synopsis/solicitation posted in May 2023. The sequencer will be delivered...
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...